TRIMTECH Therapeutics
@trimtechtx.bsky.social
Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.
A busy couple of weeks ahead for the TRIMTECH team – scroll through to see where we’ll be this September ➡️
September 12, 2025 at 2:20 PM
A busy couple of weeks ahead for the TRIMTECH team – scroll through to see where we’ll be this September ➡️
Excited to introduce our SAB! Professor Alessio Ciulli (SAB Chair) and Dr Adam Gilbert. Both are global leaders in targeted protein degradation, providing strategic guidance to advance our TRIMTAC and TRIMGLUE degraders and small molecule therapeutic pipeline.
More: shorturl.at/f76pR
More: shorturl.at/f76pR
September 2, 2025 at 9:22 AM
Excited to introduce our SAB! Professor Alessio Ciulli (SAB Chair) and Dr Adam Gilbert. Both are global leaders in targeted protein degradation, providing strategic guidance to advance our TRIMTAC and TRIMGLUE degraders and small molecule therapeutic pipeline.
More: shorturl.at/f76pR
More: shorturl.at/f76pR